HK1224211A1 - 用於治療 突變型增殖性疾病的 - Google Patents

用於治療 突變型增殖性疾病的

Info

Publication number
HK1224211A1
HK1224211A1 HK16112610.7A HK16112610A HK1224211A1 HK 1224211 A1 HK1224211 A1 HK 1224211A1 HK 16112610 A HK16112610 A HK 16112610A HK 1224211 A1 HK1224211 A1 HK 1224211A1
Authority
HK
Hong Kong
Prior art keywords
crenolanib
flt3
proliferative disorders
treating
mutated proliferative
Prior art date
Application number
HK16112610.7A
Other languages
English (en)
Inventor
．簡 維奈．
Original Assignee
Arog Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51061430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1224211(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Arog Pharmaceuticals Inc filed Critical Arog Pharmaceuticals Inc
Publication of HK1224211A1 publication Critical patent/HK1224211A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK16112610.7A 2013-01-07 2016-11-02 用於治療 突變型增殖性疾病的 HK1224211A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361749695P 2013-01-07 2013-01-07
US14/053,011 US9101624B2 (en) 2013-01-07 2013-10-14 Crenolanib for treating FLT3 mutated proliferative disorders
PCT/US2013/064821 WO2014107209A2 (en) 2013-01-07 2013-10-14 Crenolanib for treating flt3 mutated proliferative disorders

Publications (1)

Publication Number Publication Date
HK1224211A1 true HK1224211A1 (zh) 2017-08-18

Family

ID=51061430

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16112610.7A HK1224211A1 (zh) 2013-01-07 2016-11-02 用於治療 突變型增殖性疾病的

Country Status (31)

Country Link
US (7) US9101624B2 (zh)
EP (1) EP2941251B1 (zh)
JP (1) JP6288726B2 (zh)
KR (1) KR101885952B1 (zh)
CN (4) CN109966292A (zh)
AP (1) AP2015008628A0 (zh)
AU (1) AU2013371624B2 (zh)
BR (1) BR112015016282A2 (zh)
CA (1) CA2897445C (zh)
CL (1) CL2015001923A1 (zh)
CY (1) CY1120026T1 (zh)
DK (1) DK2941251T3 (zh)
EA (1) EA033910B1 (zh)
ES (1) ES2667958T3 (zh)
HK (1) HK1224211A1 (zh)
HR (1) HRP20180478T1 (zh)
HU (1) HUE038594T2 (zh)
IL (1) IL239802B (zh)
LT (1) LT2941251T (zh)
MX (1) MX369137B (zh)
NO (1) NO3019692T3 (zh)
NZ (1) NZ710720A (zh)
PE (1) PE20151525A1 (zh)
PH (1) PH12015501531B1 (zh)
PL (1) PL2941251T3 (zh)
PT (1) PT2941251T (zh)
RS (1) RS57076B1 (zh)
SG (2) SG11201505327SA (zh)
SI (1) SI2941251T1 (zh)
WO (1) WO2014107209A2 (zh)
ZA (1) ZA201505545B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI569799B (zh) 2012-09-21 2017-02-11 安羅格製藥股份有限公司 抑制組成型活性磷酸化ｆｌｔ３激酶的方法
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
MX2018010261A (es) * 2016-02-26 2019-02-11 Agios Pharmaceuticals Inc Inhibidores de idh1 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
EP3515559A4 (en) * 2016-09-20 2020-07-15 Dana-Farber Cancer Institute, Inc. COMPOSITIONS AND METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION AND TREATMENT OF AML USING USP10 BIOMARKERS AND MODULATORS
US11078541B2 (en) * 2016-11-02 2021-08-03 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
WO2021079273A1 (en) * 2019-10-21 2021-04-29 Rhizen Pharmaceuticals Ag Compositions comprising a dhodh inhibitor for the treatment of acute myeloid leukemia
WO2022019998A1 (en) * 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
US20220047574A1 (en) * 2020-08-15 2022-02-17 Arog Pharmaceuticals, Inc. Crenolanib for treating pdgfr alpha mutated proliferative disorders
EP4210847A1 (en) 2020-09-02 2023-07-19 Daniel Choi Systems and methods for augmented reality environments and tokens
US11969420B2 (en) 2020-10-30 2024-04-30 Arog Pharmaceuticals, Inc. Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
JP2023063189A (ja) * 2021-10-22 2023-05-09 アログ・ファーマシューティカルズ・インコーポレイテッド 以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990146A (en) 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
CA2303830A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
UA75055C2 (uk) * 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
EP1328519B1 (en) 2000-10-17 2005-09-07 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
PL361061A1 (en) * 2000-10-31 2004-09-20 Ciba Specialty Chemicals Holding Inc. Crystalline forms of fluvastatin sodium
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
US7101884B2 (en) 2001-09-14 2006-09-05 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
WO2003037347A1 (en) 2001-10-30 2003-05-08 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
BR0215360A (pt) 2001-12-27 2004-12-14 Theravance Inc Derivados de indolina úteis como inibidores de proteìna quinase
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
KR20050042478A (ko) 2002-08-14 2005-05-09 버텍스 파마슈티칼스 인코포레이티드 프로테인 키나아제 억제제 및 이의 용도
KR20050037585A (ko) 2002-08-23 2005-04-22 카이론 코포레이션 벤지미다졸 퀴놀리논 및 그들의 사용
PA8580301A1 (es) 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
EP1566379A4 (en) 2002-10-29 2005-11-09 Kirin Brewery QUINOLINE AND QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FLT3 AND MEDICAL COMPOSITIONS CONTAINING SAME
JP2006511616A (ja) 2002-11-13 2006-04-06 カイロン コーポレイション 癌の処置方法およびその関連方法
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
AU2003297160A1 (en) 2002-12-18 2004-07-22 Vertex Pharmaceuticals Incorporated Benzisoxazole derivatives useful as inhibitors of protein kinases
KR100787649B1 (ko) 2003-06-24 2007-12-21 화이자 프로덕츠 인크. 1-[(벤조이미다졸-1-일)퀴놀린-8-일]피페리딘-4-일아민유도체의 제조 방법
AU2006309171A1 (en) * 2005-10-28 2007-05-10 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2012052757A1 (en) * 2010-10-20 2012-04-26 Astrazeneca Ab Tumour phenotype patient selection method
CN104080461A (zh) * 2011-11-30 2014-10-01 雪松-西奈医学中心 靶向微小rna mir-409-5p、mir-379和mir-154*来治疗前列腺癌骨转移和耐药性肺癌
TWI569799B (zh) 2012-09-21 2017-02-11 安羅格製藥股份有限公司 抑制組成型活性磷酸化ｆｌｔ３激酶的方法
KR20140040594A (ko) 2012-09-26 2014-04-03 아로그 파마슈티칼스, 엘엘씨 돌연변이체 c-kit의 억제 방법
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals Inc crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado

Also Published As

Publication number Publication date
PH12015501531A1 (en) 2015-09-21
MX2015008777A (es) 2015-11-13
CN112138010A (zh) 2020-12-29
EP2941251A2 (en) 2015-11-11
US11458131B2 (en) 2022-10-04
WO2014107209A2 (en) 2014-07-10
US20180015081A1 (en) 2018-01-18
EP2941251B1 (en) 2018-03-07
CA2897445A1 (en) 2014-07-10
US10213423B2 (en) 2019-02-26
KR101885952B1 (ko) 2018-08-06
PH12015501531B1 (en) 2015-09-21
RS57076B1 (sr) 2018-06-29
NO3019692T3 (zh) 2018-06-16
AU2013371624B2 (en) 2018-02-08
US20220409610A1 (en) 2022-12-29
US20160303109A1 (en) 2016-10-20
CY1120026T1 (el) 2018-12-12
US20200390756A1 (en) 2020-12-17
CL2015001923A1 (es) 2016-01-15
US20190183879A1 (en) 2019-06-20
CN110200970A (zh) 2019-09-06
JP6288726B2 (ja) 2018-03-07
KR20150141930A (ko) 2015-12-21
IL239802A0 (en) 2015-08-31
EA201591290A2 (ru) 2016-03-31
SG11201505327SA (en) 2015-08-28
AP2015008628A0 (en) 2015-08-31
DK2941251T3 (en) 2018-03-26
AU2013371624A1 (en) 2015-08-20
US20140194464A1 (en) 2014-07-10
SG10201705611PA (en) 2017-08-30
HUE038594T2 (hu) 2018-10-29
LT2941251T (lt) 2018-04-10
EA033910B1 (ru) 2019-12-09
EA201591290A3 (ru) 2016-07-29
JP2016508148A (ja) 2016-03-17
CN109966292A (zh) 2019-07-05
ES2667958T3 (es) 2018-05-16
US9393240B2 (en) 2016-07-19
HRP20180478T1 (hr) 2018-06-15
SI2941251T1 (en) 2018-06-29
BR112015016282A2 (pt) 2017-07-11
MX369137B (es) 2019-10-30
US11007188B2 (en) 2021-05-18
EP2941251A4 (en) 2016-08-24
PT2941251T (pt) 2018-03-23
PE20151525A1 (es) 2015-10-23
IL239802B (en) 2020-06-30
NZ710720A (en) 2020-06-26
CA2897445C (en) 2019-04-30
PL2941251T3 (pl) 2018-07-31
US9801870B2 (en) 2017-10-31
ZA201505545B (en) 2016-10-26
US20150238479A1 (en) 2015-08-27
CN105555272A (zh) 2016-05-04
US9101624B2 (en) 2015-08-11

Similar Documents

Publication Publication Date Title
HRP20180478T1 (hr) Crenolanib za liječenje flt3 mutiranih proliferativnih poremećaja
GB201314176D0 (en) Unipod rotating apparatus
SG11201603050TA (en) Methods for treating cancers
GB201420103D0 (en) Treating particles
GB2512025B (en) Surface treatment device
SG10201407984XA (en) Polishing apparatus
EP2960025A4 (en) RETAINING DEVICE
IL243570A0 (en) Combined treatment for atopic dermatitis
HK1215164A1 (zh) 處理方法
SG10201407798XA (en) Polishing apparatus
SG10201404675XA (en) Deposition apparatus
PL2941584T3 (pl) Środki chwytające
GB201316467D0 (en) Lifting apparatus
SG10201403993VA (en) Polishing apparatus
GB2521920B (en) Lifting apparatus
GB201312419D0 (en) Manipulation treatment apparatus
GB201401174D0 (en) pPost raising apparatus
HK1218191A1 (zh) 吞吐量表徵
EP3082251A4 (en) MOTOR DRIVE DEVICE
SG11201509066UA (en) Deposition apparatus
GB201305609D0 (en) Nursery apparatus
IL228606A0 (en) Surface treatment process
GB201310085D0 (en) Heating apparatus
GB201305598D0 (en) Heating apparatus
GB201321531D0 (en) Treatment for cancers